Global Search

Hide Filters

Showing 1682 results

Ad hoc release / Jun 29, 2018

Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn

Alcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create…
Press release / Sep 05, 2017

Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS

Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet…
Press release / Oct 23, 2018

Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig® where other treatments have failed

The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported…
Press release / Jun 02, 2016

Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)

Afinitor fills critical need in EU as first approved therapy for advanced, progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Nonfunctional GI and lung NET are…
Press release / Apr 14, 2022

Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio

Brimonidine tartrate/timolol maleate combination eyedrop is used to treat elevated eye pressure in patients with ocular hypertension1 Ocular hypertension affects over 5% of all adults2; the…
Press release / Jan 06, 2017

Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders

Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with…
Press release / Sep 21, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the…
Press release / Sep 21, 2018

Novartis announces positive CHMP opinion for one-time gene therapy Luxturna® to treat children and adults with rare inherited retinal disease

If approved in expected timeframe, Luxturna* (voretigene neparvovec) will be first and only gene therapy available in EU to treat a rare inherited retinal disease Children and adults…
Press release / May 15, 2018

Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)

ARROW study to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya®*) in clearing of Stelara®*-resistant psoriatic plaques[1] This is the…
Press release / Sep 11, 2018

Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis

Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has…